Stifel on Rhythm Pharmaceuticals (RYTM): 'Bivamelagon Data Look Very Solid and Meet/Exceed Our Bar'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $94.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst comments "We’re ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
